Literature DB >> 11170627

Cytotoxic responses to aromatic ring and configurational variations in alpha-conidendrin, podophyllotoxin, and sikkimotoxin derivatives.

A Dantzig1, R T LaLonde, F Ramdayal, R L Shepard, K Yanai, M Zhang.   

Abstract

Derivatives of alpha-conidendrin, podophyllotoxin, and sikkimotoxin were prepared to evaluate the cytotoxic contributions of C-4 configuration and pendant and fused arene substitutions. Dimethyl-alpha-conidendryl alcohol (5), 9-deoxypodophyllol (6), and 9-deoxysikkimol (17) were dehydrated to their respective oxolane derivatives 4, 3, and 9. Diols 5 and 6 were converted via oxabicyclo[3.2.1]octanols 10 and 14 to target oxolanes 8 and 7 where C-4 had been inverted relative to that in 3 and 4. Cytotoxicities of the five oxolanes were determined in two drug-sensitive human leukemia and two multidrug-resistant cell lines expressing P-glycoprotein or multidrug-resistance associated protein (MRP). Changing the pendant arene configuration or replacing a m-methoxy by hydrogen resulted in a 100-fold cytotoxicity loss. Replacing a methylenedioxy group in the fused arene by two methoxy substituents reduced cytotoxicity by 10-fold. Drug-resistant cell lines were equally resistant to compounds 3, 4, 8, and 9 indicating that these four compounds do not serve as substrates of the transport proteins P-glycoprotein and MRP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170627     DOI: 10.1021/jm990563p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Synthesis and biological evaluation of new 4beta-5-Fu-substituted 4'-demethylepipodophyllotoxin derivatives.

Authors:  Fu-Min Zhang; Xiao-Jun Yao; Xuan Tian; Yong-Qiang Tu
Journal:  Molecules       Date:  2006-11-02       Impact factor: 4.411

Review 2.  Recent strategies and tactics for the enantioselective total syntheses of cyclolignan natural products.

Authors:  Rebekah G Reynolds; Huong Quynh Anh Nguyen; Jordan C T Reddel; Regan J Thomson
Journal:  Nat Prod Rep       Date:  2022-03-23       Impact factor: 13.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.